<code id='05D6A55355'></code><style id='05D6A55355'></style>
    • <acronym id='05D6A55355'></acronym>
      <center id='05D6A55355'><center id='05D6A55355'><tfoot id='05D6A55355'></tfoot></center><abbr id='05D6A55355'><dir id='05D6A55355'><tfoot id='05D6A55355'></tfoot><noframes id='05D6A55355'>

    • <optgroup id='05D6A55355'><strike id='05D6A55355'><sup id='05D6A55355'></sup></strike><code id='05D6A55355'></code></optgroup>
        1. <b id='05D6A55355'><label id='05D6A55355'><select id='05D6A55355'><dt id='05D6A55355'><span id='05D6A55355'></span></dt></select></label></b><u id='05D6A55355'></u>
          <i id='05D6A55355'><strike id='05D6A55355'><tt id='05D6A55355'><pre id='05D6A55355'></pre></tt></strike></i>

          
          WSS
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          Wikipedia